Position for potential regulatory filings and approval acceleration; monitor upcoming medical meeting presentations for detailed efficacy and safety data. Consider incremental value of Ultomiris expansion into IgAN, a high-unmet-need market with limited current therapies.
Price Chart
Executive Summary
AstraZeneca announced positive interim results from the Phase III I CAN trial, showing that Ultomiris (ravulizumab) met its primary endpoint with a statistically significant and clinically meaningful reduction in proteinuria in adults with immunoglobulin A nephropathy (IgAN). The company plans to seek accelerated approval in key markets and present full results at a future medical meeting.
Key Facts
- Ultomiris met the primary endpoint of statistically significant and clinically meaningful reduction in proteinuria (measured by 24-hour UPCR) at week 34 in the I CAN Phase III trial.
- The trial enrolled approximately 510 adults with IgAN at risk of disease progression across 28 countries.
- Ultomiris demonstrated rapid reduction in proteinuria as early as week 10.
- The safety profile was consistent with known data, with no new safety concerns.
- AstraZeneca plans to file for accelerated approval in key markets and present results at a forthcoming medical meeting.
Financial Impact
High potential revenue upside given the unmet need in IgAN and the drug's prior approval in other rare diseases; market opportunity supported by over 560,000 diagnosed patients in US, EU5, and Japan.
Risk Factors
- Final trial results at week 106 (eGFR change) may not confirm long-term benefit.
- Regulatory agencies may require additional data beyond the interim analysis for full approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003757 |
| Document: 0001654954-26-003757-index-headers.html | 0001654954-26-003757 |
| Document: 0001654954-26-003757-index.html | 0001654954-26-003757 |
| Document: 0001654954-26-003757.txt | 0001654954-26-003757 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $157.02 (−2.98%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $157.02 (+4.13%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $157.02 (−1.89%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $157.02 (+3.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access